In light of the strong indication that they act as upstream drivers of T2-mediated disease, TSLP, IL-33, and IL-25 have attracted a lot of interest as potential therapeutic targets in asthma, and monoclonal antibodies targeting TSLP and IL-33 are currently under clinical evaluation. Here, IL33 is linked to asthma.